Title: Alendronate Sodium in Osteoarthritis: Effects on Lipid Profile, Circulating Leptin and the Clinical Activity
Authors: Sinaa Abdul Amir Kadhim, Haidar Mahdi Jawad, Sami Salman Shihab
DOI: https://dx.doi.org/10.18535/jmscr/v5i3.109
Abstract
Objective: Osteoarthritis (OA) is a most common arthritic disease and responsible for more of disability in all world. OA affects all joint and characterized by degredation of cartilage, subchondral bone turnover and osteophytes formation.
Aim of the study: To evaluate the effectiveness of alendronate sodium (ALN) on disease activity and physical function, evaluate the lipid profile and study the impact of ALN on circulating leptin marker and myeloperoxidase (MPO) and to determine its effectiveness in slowing progression of disease.
Patients and methods:116 OA patients over 45 years old with X-ray grade II and more of Kellgren and Lawrence grading were enrolled in our study. Base line assessment was done, Kellgren and Lawrence X-ray grading, WOMAC scoring, body mass index and the lipid profil with enzyme-linked immunosorbent assay (ELISA) analysis of serum leptin and MPO. They were instructed to take ALN 10 mg daily. Reassessment was done after 3 months.
Results: A significant symptomatic improvement in WOMAC scoring (pain, stiffness) were observed associated with significant reduction in serum leptin and no significant reduction in MPO. A nonsignificantchanges in lipid profile, joint space width and function were also reported.
Conclusion: ALN in patients with OA has clinical efficacy in reducing suffering especially pain probably through inhibition of leptin with no significant joint structural improvement, and may help delay and prevent further disease progression probably through inhibition of leptinactivity.
References
1. Abdel-Sater K and Mansour H. Bone biomarkers of ovariectomised rats after leptin therapy. BratislLekListy. 2013; 114(6):303-307.
2. Abramson S, Attur M, Yazici Y. Prospects for disease modification in osteoarthritis. Nat ClinPractRheumatol 2006;2:304–12.
3. Alshami A. Knee osteoarthritis related pain: a narrative review of diagnosis and treatment. Int J Health Sci (Qassim). 2014 Jan; 8(1): 85–104.
4. Atsuko S, Jean O, Takeshi M, et al. Scoliosis in osteogenesisimperfecta caused by COL1A1/ COL1 A2 mutations —genotype–phenotype. correlations and effect of bisphosphonate treatment Bone May 2016 Volume 86, Pages 53–57.
5. Bijlsma J, Berenbaum F, Lafeber F. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377:2115–26.
6. Blagojevic M, Jinks C, Jeffery A et al. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2010, 18: 24-33.Brandt K, Dieppe P, Radin E. "Etiopathogenesis of osteoarthritis". Med. Clin. North Am. January 2009 93 (1): 1–24. Brandt K,Mankin H, Shulman L. Workshop on etiopathogenesis of osteoarthritis, J Rheumatol 1986,13, 1126-1160.
7. Calvo E, Castaneda S, Largo R, et al. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 2007;15:69–77.
8. Carbone L, Nevitt M, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004; 50(11): 3516-3525.
9. De Boer T, Van Spil W, Huisman A, et al. Serum adipokines in osteoarthritis ;comparison with controls and relationship with local parameters of synovialinfla-mmation and cartilage damage. Osteoarthritis Cartilage 2012.
10. Deberg M, Dubuc J, Labasse A, et al. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 2008;67:168-174.
11. Falk A, Benbouazza K, Amine B, et al. Translation and validation of Moroccan Western Ontario and McMaster Universities (WOMAC) osteoarthritis index in knee osteoarthritis. Rheumatol Int. 2008;28:677-683.
12. Ginckel A, Bennell K, Campbell P, et al. Location of knee pain in medial knee osteoarthritis: patterns and associations with self-reported clinical symptoms. Osteoarthritis and Cartilage July 2016 Volume 24, Issue 7, Pages 1135–1142.
13. Goldring M, Goldring S. Osteoarthritis. J Cell Physiol. 2007; 213(3) : 626 –634.
14. Grover A, Samson S. Benefits of antioxidant supplements for knee osteoarthritis: rationale and reality. Nutr J. 2016 Jan 5;15:1.
15. Hawker G, Stewart L, French M, et al. Understanding the pain experience in hip and knee osteoarthritis—an OARSI/ OMERACT initiative. Osteoarthritis Cartilage. 2008;16(4):415–22
16. Hochberg M. Osteoarthritis, B. Clinical features. In :Klippel JH, Crofford LJ, Stone JH, Weyand CM, eds. Primer on the Rheumatic Diseases,12thed.Atlanta, Georgia :Arthritis Foundation,2001,289-293.
17. Huang Z, Du S, Huang L, et al. Leptin promotes apoptosis and inhibits autophagy of chondrocytes through upregulatinglysyl oxidase-like 3 during osteoarthritis pathogenesis. Osteoarthritis Cartilage. 2016 Jul; 24(7):1246-1253.
18. Huang Z, Li J, Du S et al. One. Effects of UCP4 on the Proliferation and Apoptosis of Chondrocytes: Its Possible Involvement and Regulation in Osteoarthritis. 2016; 11(3):e0150684.
19. Hunter D. Advanced imaging in osteoarthritis. Bull NYU HospJt Dis. 2008. 66(3):251-60.
20. Hu H, Zhang L, Li B, et al. In vitro effect of alendronate on chondrocytes and articular cartilage and subchondral bone in rabbit anterior cruciate ligament transection model. ZhongguoXiu Fu Chong Jian WaiKe ZaZhi. 2009 Dec; 23(12):1474-81.
21. Iwamoto J., Sato Y, Uzawa M, Takeda T, et al. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis,” Yonsei Medical Journal 2008; 49 (1): 119–128.
22. Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 2002; 100: 55–64.
23. Jokar M, Mirfeizi Z, Keyvanpajoh K. The Effect of Alendronate on Symptoms of Knee Osteoarthritis: A Randomized Controlled Trial. Iranian Journal of Medical Sciences IJMS (2010) Vol 35, No 1:9-15.
24. Karsdal M , Bay-Jensen A , Lories R, et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? : Ann Rheum Dis 2014;73:336-348.
25. Kellgren J, Lawrence J. Radiological assessment of osteoarthrosis. Ann Rheum Dis. 1957;16:494–502.
26. Kon E, Filardo G, Drobnic M, et al. Madry H, Jelic M, Dijk N, et al. Non-surgical management of early knee osteoart-hritis. Knee Surg Sports Traumatol Arthrosc. 2012;20:436–9.
27. Kosuke K, Hidemasa K, Mari A, et al. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. Journal of Bone and Mineral Research Volume 25, Issue 12.December 2010 Pages 2582–2591.
28. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents. closing the gate on Toll-like receptors?Arthritis Rheum. (2006);54:3068–3070.
29. Lampropoulou K, Dontas I, Stathopoulos I, et al. Chondroprotective effect of high-dose zoledronic acid: an experimental study in a rabbit model of osteoarthritis. J Orthop Res, 32 (2014), pp. 1646–1651.
30. Laslett L, Kingsbury S, Hensor E, et al. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative.Ann Rheum Dis, 73 (2014), pp. 824–830.
31. Loeser R, Goldring S, Scanzello C, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–1707.
32. Lübbeke A, Finckh A, Puskas G, et al. Do synovial leptin levels correlate with pain in end stage arthritis?.IntOrthop. 2013 Oct; 37(10):2071-9. Epub 2013 Jul 9.
33. Mahjoub M, Berenbaum F, Houard X. Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int. 2012 ;23(Suppl 8):841–846.
34. Michael J, Julie C, Fraser P, et al. Biochemical and molecular mechanisms of action of bisphosphonates.BoneVolum 49, Issue 1, July 2011, Pages 34–41.
35. Mohan G, Perilli E, Parkinson I. et al. Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort. Osteoarthritis Cartilage. 2013 Oct;21(10):1595-604.
36. Neogi M, Ensrud K, Bauer D, et al. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008;67:1427-1430.
37. Nijs R, Jacobs J, Lems W, et al. Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis N Engl J Med 2006; 355:675-684August 17, 2006.
38. Nishii T, Tamura S, Shiomi T, et al. Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial.ClinRheumatol (2013); 32(12): pp. 1759–1766.
39. Oliver P, Yuelong C, Benny A, et al. Cross-sectional and longitudinal associations between circulating leptin and knee cartilage thickness in older adults. Ann Rheum Dis 2015;74:82–88.
40. Orwoll E, Miller P, Adachi J, et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study. JBMR Volume 25, Issue 10October 2010 Pages 2239–2250. 9:21–6.
41. Pottie P, Presle N, Terlain B, et al. Obesity and osteoarthritis: more complex than predicted!. Ann Rheum Dis 2006;65: 1403–1405.
42. Presle N, Pottie P, Dumond H, et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 2006;14:690–5.
43. Punzi L. Coll2-1, Coll2-1NO2 and myeloperoxidase serum levels in erosive and non-erosive osteoarthritis of the hands. Osteoarthritis Cartilage 2012; 20:557e61.
44. Reid I and Hosking D. Bisphosphonates in Paget's disease. BoneVolume 49, Issue 1, July 2011, Pages 89–94.
45. Reseland J, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. Journal of Bone & Mineral Research 2001; 16: 1426–1433.
46. Scanzello C and GoldringS.The role of synovitis in osteoarthritis pathogenesis. Bone. 2012 Aug; 51(2):249-57.Scotece M and Mobasheri A. Leptin in osteoarthritis: Focus on articular cartilage and chondr-ocytes. Life Sci. 2015 Nov 1;140:75-8.
47. Sebastién-Ochoa A, Fernández-Garcia D, Reyes-García R, et al. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate. Menopause. 2012;19:172–177.
48. Sellam J and Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625–635.Shirai T, Kobayashi M, Nishitani K, et al. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res. 2011 Oct;29(10):1572-7.
49. Siebelt M, Waarsing J, Groen H, et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone, 66 (2014), pp. 163–170.
50. Sookvanichsilp N, Tad-urai N, Lawtong P, et al. Effects of Antiresorptive Drugs on Long Bone Growth, Body Weight Gain, and Serum Lipid Levels in Young Adult Ovariectomized Rats. Mahidol University Journal of Pharmaceutical Sciences 2014; 41 (4), 29-38.
51. Spector T. Bisphosphonates: Potential therapeutic agents for disease modification in osteoarthritis Aging Clinical and Experimental Research October 2003, Volume 15, Issue 5, pp 413-418.
52. Steinbeck J, Nesti J, Sharkey P, et al. Myeloperoxidase and chlorinated peptides in osteoarthritis: potential biomarkers of the disease. Journal of Orthopedic ResearchVolume 25, Issue 9September 2007 Pages 1128–1135.
53. Suri P, Morgenroth D, Hunter D. Epidemiology of osteoarthritis and associated comorbidities. PM R J. 2012, 4: S10 S19.10.
54. Vuolteenaho K, Koskinen A, Moilanen E. Leptin - a link between obesity and osteoarthritis. applications for prevention and treatment. Basic ClinPharmacol Toxicol. 2014 Jan;114(1):103-8. doi: 10.1111/bcpt.12160. Epub 2013 Nov 20.
55. Wang Z, Wang W, Zhang L, et al . Effect of alendronate on interleukin-1beta induced chondrocytes of rat in vitro. ZhongguoXiu Fu Chong JianWaiKeZaZhi. 2011Jan;25(1):50-5.
56. Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69:483–9.
Zhang ZM, Shen C, Li H, et al.Leptin induces the apoptosis of chondrocytes in an in vitro model of osteoarthritis via the JAK2‑STAT3 signaling pathway. Mol Med Rep. 2016 Apr; 13(4):3684-90